Sign in to view content

Eighteen-Month Results From the Phase 1b-2 Study of Tinlarebant in Adolescent Subjects with Stargardt Disease

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

Video
Published 2023

Related

Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease
Quan Dong Nguyen, MD, MSc, FARVO, FASRS
Annual Meeting Talks
2024
Imaging Predictors of Functional Outcomes Following Rhegmatogenous Retinal Detachment Repair
WEI WEI LEE, MD
Rajeev H. Muni, MD, MSC, FRCS(C), FASRS
Updates from the Field
2022
MCO-010 Optogenetic Therapy for Severe Vision Loss in Stargardt Disease: 6-Month Outcomes From the Phase 2 STARLIGHT Trial
Allen C Ho, MD FASRS
Annual Meeting Talks
2023

Category: Hereditary Retinal Disease & Genetics

See more